Volume 20 Issue 10
Oct.  2022
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2022  >  20(10): 1688-1690
HUANG Jin, ZHU Cheng. Effects of paliperidone sustained-release tablets combined with aripiprazole on psychotic symptoms, cognitive function and prolactin in schizophrenia[J]. Chinese Journal of General Practice, 2022, 20(10): 1688-1690. doi: 10.16766/j.cnki.issn.1674-4152.002680
Citation: HUANG Jin, ZHU Cheng. Effects of paliperidone sustained-release tablets combined with aripiprazole on psychotic symptoms, cognitive function and prolactin in schizophrenia[J]. Chinese Journal of General Practice, 2022, 20(10): 1688-1690. doi: 10.16766/j.cnki.issn.1674-4152.002680
shu

Effects of paliperidone sustained-release tablets combined with aripiprazole on psychotic symptoms, cognitive function and prolactin in schizophrenia

doi: 10.16766/j.cnki.issn.1674-4152.002680
  • 1.

    Second Department of Psychiatry, the Fourth People' s Hospital of Jiande, Hangzhou, Zhejiang 311612, China

Funds:

 2022517135

  • Received Date: 2022-03-22
    Available Online: 2022-11-30
    Abstract
  •   Objective  To investigate alleviation of psychotic symptoms and cognitive function of schizophrenia and the effect of prolactin in the combined treatment of paliperidone sustained-release tablets and aripiprazole.  Methods  Ninety-six patients with schizophrenia were recruited at the Fourth People' s Hospital of Jiande from September 2019 to September 2021 and randomly divided into intervention group (n=48) and control group (n=48) with the random number table method. The patients in the intervention group received paliperidone sustained-release tablets combined with aripiprazole at 10 mg/day, and the control group received paliperidone sustained-release tablets. Changes in positive and negative syndrome scale (PANSS), MATRICS consensus cognitive battery (MCCB) and prolactin were observed in both groups after 8 weeks of treatment.  Results  After treatment, the PANSS and MCCB scores improved (all P < 0.001) and prolactin levels increased (P < 0.001) in both groups. The scores of PANSS [intervention group, (65.06±10.47) points, control group, (70.17±6.36) points, P=0.005], information processing speed [intervention group, (55.06±6.48) points, control group, (49.85±4.76) points, P < 0.001], attention/vigilance [intervention group, (54.33±9.37) points, control group, (48.94±5.31) points, P=0.001], working memory [intervention group, (50.33±5.65) points, control group, (45.96±4.65) points, P < 0.001], prolactin levels [intervention group, (46.52±2.59) ng/mL, control group, (65.63±8.32) ng/mL, P < 0.001] in the intervention group were better than the control group. No statistically significant difference in word learning, visual learning, reasoning and problem-solving ability and social cognition was found between the two groups after treatment (all P>0.05).  Conclusion  Paliperidone sustained-release tablets combined with aripiprazole can effectively alleviate psychotic symptoms and cognitive function in schizophrenia. Aripiprazole can reduce the hyperprolactin level caused by paliperidone extended-release tablets.

     

    • FullText(HTML)
  • loading
    • References(23)
  • [1]
    HARVEY P D, BOSIA B, CAVALLARO R, et al. Cognitive dysfunction in schizophrenia: An expert group paper on the current state of the art[J]. Schizophr Res Cogn, 2022, 29: 100249. DOI: 10.1016/j.scog.2022.100249.
    [2]
    JAUHAR S, JOHNSTONE M, MCKENNA P J. Schizophrenia[J]. Lancet, 2022, 399(10323): 473-486. doi: 10.1016/S0140-6736(21)01730-X
    [3]
    MCCUTCHEON R A, REIS MARQUES T, HOWES O D. Schizophrenia-an Overview[J]. JAMA Psychiatry, 2020, 77(2): 201-210. doi: 10.1001/jamapsychiatry.2019.3360
    [4]
    KAAR S J, NATESAN S, MCCUTCHEON R, et al. Antipsychotics: Mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology[J]. Neuropharmacology, 2020, 172: 107704. DOI: 10.1016/j.neuropharm.2019.107704.
    [5]
    LEUCHT S, CIPRIANⅡ A, SPINELI L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis[J]. Lancet, 2013, 382(9896): 951-962. doi: 10.1016/S0140-6736(13)60733-3
    [6]
    许超. 阿立哌唑治疗利培酮所致女性精神分裂症患者高催乳素血症的临床效果及对性激素水平、子宫内膜厚度的影响[J]. 医学临床研究, 2021, 38(4): 617-619. doi: 10.3969/j.issn.1671-7171.2021.04.041

    XU C. Clinical effect of aripiprazole on hyperprolactinemia in female patients with schizophrenia caused by risperidone and its effect on sex hormone levels and endometrial thickness[J]. Journal of Clinical Research, 2021, 38(4): 617-619. doi: 10.3969/j.issn.1671-7171.2021.04.041
    [7]
    TASAKI M, YASUI-FURUKORI N, KUBO K, et al. Relationship of prolactin concentrations to steady-state plasma concentrations of aripiprazole in patients with schizophrenia[J]. Ther Drug Monit, 2021, 43(4): 589-592. doi: 10.1097/FTD.0000000000000843
    [8]
    CHEN J X, SU Y A, BIAN Q T, et al. Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose-response study[J]. Psychoneuroendocrinology, 2015, 58: 130-140. doi: 10.1016/j.psyneuen.2015.04.011
    [9]
    KAY S R, FISZBEINI A, OPLER L A. The positive and negative syndrome scale (PANSS) for schizophrenia[J]. Schizophr Bull, 1987, 13(2): 261-276. doi: 10.1093/schbul/13.2.261
    [10]
    SHI C, KANG L, YAO S Q, et al. The MATRICS consensus cognitive battery (MCCB): Co-norming and standardization in China[J]. Schizophr Res, 2015, 169(1-3): 109-115. doi: 10.1016/j.schres.2015.09.003
    [11]
    MARCUS S C, ZUMMO J, PETTIT A R, et al. Antipsychotic adherence and rehospitalization in schizophrenia patients receiving oral versus long-acting Injectable antipsychotics following hospital discharge[J]. J Manag Care Spec Pharm, 2015, 21(9): 754-768.
    [12]
    MAURI M, MAURI M C, ADAMI M, et al. Efficacy and tolerability of paliperidone ER in patients with unsatisfactorily controlled schizophrenia by other antipsychotics: A flexible-dose approach[J]. Int Clin Psychopharmacol, 2015, 30(6): 329-337. doi: 10.1097/YIC.0000000000000092
    [13]
    WU R Q, LIN C G, ZHANG W, et al. Effects of risperidone and paliperidone on brain-derived neurotrophic factor and N400 in first-episode schizophrenia[J]. Chin Med J (Engl), 2018, 131(19): 2297-2301. doi: 10.4103/0366-6999.241802
    [14]
    PEITL V, STEFANOVIC M, ORLOVIC I, et al. Long acting aripiprazole influences cognitive functions in recent onset schizophrenia[J]. Psychopharmacology (Berl), 2021, 238(6): 1563-1573. doi: 10.1007/s00213-021-05788-w
    [15]
    周波, 冯杰. 利培酮联合阿立哌唑对慢性精神分裂症患者认知功能及社会功能的影响[J]. 医学临床研究, 2019, 36(8): 1533-1535. doi: 10.3969/j.issn.1671-7171.2019.08.028

    ZHOU B, FENG J. Effects of risperidone combined with aripiprazole on cognitive function and social function in patients with chronic schizophrenia[J]. Journal of Clinical Research, 2019, 36(8): 1533-1535. doi: 10.3969/j.issn.1671-7171.2019.08.028
    [16]
    MINWALLA H D, WRZESINSKI P, DESFORGES A, et al. Paliperidone to treat psychotic disorders[J]. Neurol Int, 2021, 13(3): 343-358. doi: 10.3390/neurolint13030035
    [17]
    黄越. 阿立哌唑联合氟伏沙明治疗强迫症的临床疗效安全性及对患者生存质量的影响[J]. 河北医学, 2018, 24(12): 2048-2051. doi: 10.3969/j.issn.1006-6233.2018.12.028

    HUANG Y. Clinical efficacy, safety and quality of life of aripiprazole combined with fluvoxamine in the treatment of obsessive-compulsive disorder[J]. Hebei Medicine, 2018, 24(12): 2048-2051. doi: 10.3969/j.issn.1006-6233.2018.12.028
    [18]
    陈钱芳, 沈志华. 阿立哌唑联合认知干预对精神分裂症患者认知功能及生活质量的影响[J]. 中国现代医生, 2019, 57(2): 77-80. https://www.cnki.com.cn/Article/CJFDTOTAL-ZDYS201902022.htm

    CHEN Q F, SHEN Z H. Effect of aripiprazole combined with cognitive intervention on cognitive function and quality of life in patients with schizophrenia[J]. China Mode Doct, 2019, 57(2): 77-80. https://www.cnki.com.cn/Article/CJFDTOTAL-ZDYS201902022.htm
    [19]
    罗晓东, 吕跃中, 贾雪珍, 等. 阿立哌唑联合丁螺环酮治疗精神分裂症的效果及安全性分析[J]. 中华全科医学, 2021, 19(1): 83-85, 123. doi: 10.16766/j.cnki.issn.1674-4152.001737

    LUO X D, LV Y Z, JIA X Z, et al. Efficacy and safety of aripiprazole combined with buspirone in the treatment of schizophrenia[J]. Chinese Journal of General Practice, 2021, 19(1): 83-85, 123. doi: 10.16766/j.cnki.issn.1674-4152.001737
    [20]
    MALLET J, GORWOOD P, LE STRAT Y, et al. Major depressive disorder (MDD) and schizophrenia- addressing unmet needs with partial agonists at the D2 receptor: A review[J]. Int J Neuropsychopharmacol, 2019, 22(10): 651-664. doi: 10.1093/ijnp/pyz043
    [21]
    ZHANG J P, CHENG X, ZHANG H H, et al. Analysis of the status of drug treatment in 746 inpatients with early-onset schizophrenia in China: A retrospective study[J]. BMC Psychiatry, 2021, 21(1): 10. doi: 10.1186/s12888-020-02962-w
    [22]
    MACOTELA Y, TTIEBEL J, CLAPP C. Time for a new perspective on prolactin in metabolism[J]. Trends Endocrinol Metab, 2020, 31(4): 276-286. doi: 10.1016/j.tem.2020.01.004
    [23]
    FANTA T, HAILE K, ABEBAW D, et al. Assessment of sexual dysfunction and associated factors among patients with schizophrenia in Ethiopia, 2017[J]. BMC Psychiatry, 2018, 18(1): 158.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (421) PDF downloads(15) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return